STEVEN C GILMAN
CIK 1379970 · CEO · last filed 2025-06-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$849.5K
Companies
9
Total Filings
133
Lifetime Open-Market Net
-$17.97M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SCYX | Director | 70,000 | $4.23 | $296.1K | $25.0K | 27 | 2025-06-30 |
| AKBA | Director | 152,830 | $0.92 | $141.3K | -$52.1K | 11 | 2025-06-11 |
| VCEL | Director | 11,000 | $37.46 | $412.1K | -$2.23M | 22 | 2024-10-18 |
| CONTRAFECT Corp (CFRX) Delisted | Director | 20,800 | $0.05 | $1.0K | $992 | 9 | 2022-05-18 |
| MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Director | 0 | — | — | -$1.10M | 10 | 2020-10-01 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Director | 0 | — | — | -$13.8K | 6 | 2018-12-13 |
| CONTRAFECT Corp (CFRX.W) Delisted | CEO | 20,000 | — | — | $49.6K | 3 | 2016-07-27 |
| CUBIST PHARMACEUTICALS INC (CBST.Z) Delisted | EVP & Chief Scientific Officer | 2,851 | — | — | -$9.24M | 10 | 2015-01-21 |
| CUBIST PHARMACEUTICALS INC (CBST) Delisted | EVP & Chief Scientific Officer | 26,269 | — | — | -$5.41M | 35 | 2013-07-02 |
Recent Filings · Page 5 of 14
133 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-08-15 | CONTRAFECT Corp (CFRX) Delisted | — | — | $0 | EDGAR |
| 2019-06-21 | MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Mixed | +4,356 | $0 | EDGAR |
| 2019-06-20 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2019-06-10 | AKBA | Grant (A) | +13,700 | $0 | EDGAR |
| 2019-05-29 | CONTRAFECT Corp (CFRX) Delisted | — | — | $0 | EDGAR |
| 2019-05-03 | VCEL | Mixed | — | -$105.4K | EDGAR |
| 2019-03-04 | VCEL | Mixed | — | -$114.4K | EDGAR |
| 2019-02-07 | CONTRAFECT Corp (CFRX) Delisted | — | — | $0 | EDGAR |
| 2019-01-04 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2018-12-13 | AKBA | Grant (A) | +10,231 | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.